[HTML][HTML] UNcommon EGFR mutations: international case series on efficacy of osimertinib in real-life practice in first-LiNe setting (UNICORN)
Introduction Approximately 10% of EGFR mutations (EGFRmuts) are uncommon
(ucEGFRmuts). We aimed to collect real-world data about osimertinib for patients with …
(ucEGFRmuts). We aimed to collect real-world data about osimertinib for patients with …
LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts
S Ramalingam, JCH Yang, CK Lee, T Kurata… - Journal of Thoracic …, 2016 - jto.org
Background Osimertinib (AZD9291) is a potent, irreversible EGFR-TKI selective for EGFR-
TKI-sensitising (EGFRm) and T790M resistance mutations. We present updated efficacy and …
TKI-sensitising (EGFRm) and T790M resistance mutations. We present updated efficacy and …
[HTML][HTML] EGFR mutation analysis for prospective patient selection in two phase II registration studies of osimertinib
Introduction Osimertinib is an oral, central nervous system–active, EGFR tyrosine kinase
inhibitor (TKI) for the treatment of EGFR T790M–positive advanced NSCLC. Here we have …
inhibitor (TKI) for the treatment of EGFR T790M–positive advanced NSCLC. Here we have …
[HTML][HTML] Osimertinib in NSCLC with atypical EGFR-activating mutations: A retrospective multicenter study
J Ji, JV Aredo, A Piper-Vallillo, L Huppert… - JTO Clinical and …, 2023 - Elsevier
Introduction EGFR mutations drive a subset of NSCLC. Patients harboring the common
EGFR mutations, deletion of exon 19 and L858R, respond well to osimertinib, a third …
EGFR mutations, deletion of exon 19 and L858R, respond well to osimertinib, a third …
Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
S Ramalingam, T Reungwetwattana… - Annals of …, 2017 - annalsofoncology.org
Background: Osimertinib is a third-generation, CNS-active EGFR-TKI that potently and
selectively inhibits both EGFRm and EGFR T790M resistance mutations. Pre-and early …
selectively inhibits both EGFRm and EGFR T790M resistance mutations. Pre-and early …
Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study
N Peled, W Kian, E Inbar, IM Goldstein… - Neuro-oncology …, 2022 - academic.oup.com
Background Osimertinib is selective for both epidermal growth factor receptor (EGFR)-
tyrosine-kinase inhibitor (TKI) sensitizing and Thr790Met mutations. While intracranial …
tyrosine-kinase inhibitor (TKI) sensitizing and Thr790Met mutations. While intracranial …
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation
JB Auliac, M Pérol, D Planchard, I Monnet, M Wislez… - Lung Cancer, 2019 - Elsevier
Objectives The efficacy of osimertinib in pretreated patients with advanced non-small cell
lung cancer (NSCLC) harboring EGFR T790 M resistance mutation was demonstrated in …
lung cancer (NSCLC) harboring EGFR T790 M resistance mutation was demonstrated in …
[HTML][HTML] A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or …
Background Up to 40% of patients with non-small-cell lung cancer (NSCLC) and epidermal
growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) …
growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) …
Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The …
L Xing, Y Pan, Y Shi, Y Shu, J Feng, W Li, L Cao… - Clinical Cancer …, 2020 - AACR
Purpose: Dynamic biomarker monitoring may inform pathways for treating EGFR-T790M–
positive non–small cell lung cancer (NSCLC) and central nervous system (CNS) metastases …
positive non–small cell lung cancer (NSCLC) and central nervous system (CNS) metastases …
Osimertinib for EGFR‐Mutant Lung Cancer with Brain Metastases: Results from a Single‐Center Retrospective Study
Introduction Osimertinib is a third‐generation tyrosine kinase inhibitor, initially approved for
epidermal growth factor receptor (EGFR) mutant non‐small cell lung cancer (NSCLC) with …
epidermal growth factor receptor (EGFR) mutant non‐small cell lung cancer (NSCLC) with …